Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Lannett announced that it has received approval for Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, the generic version of Oak’s Cosopt.
Cosopt ophthalmic solution is indicated for use in open-angle glaucoma or ocular hypertension where beta-blocker alone is inadequate. It combines dorzolamide, a carbonic anhydrase inhibitor (sulfonamide), and timolol, a noncardioselective beta-blocker. Both components decrease elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.
Dorzolamide HCl and Timolol Maleate Ophthalmic Solution will be available in a 2%/0.5% strength in the next few months.
For more information visit Lannett.com.
